Bayers, Pharma

Bayer's Pharma Upside Is Real, but Berenberg Won't Chase the Stock

Published on 11/18/2026 at 20:20 | Editorial boerse-global.de
Berenberg forecasts EUR 5 billion EBITDA for Bayer's pharma division in 2027, above consensus, but keeps a Hold rating after a 51% share rally.
Bayers, Pharma, Upside, Real, Berenberg, Wont, Chase, Stock, EUR, EBITDA Illustration mit AI erstellt.

Berenberg has staked out a more bullish view of Bayer's pharmaceutical division than the wider market, forecasting EUR 5 billion in EBITDA for 2027 against a consensus of EUR 4.8 billion. The call rests on two named growth drivers — Nubeqa and Kerendia — and it lands at an awkward moment for the stock, which has already climbed 51% since the start of the year.

That rally explains why a stronger business outlook alone hasn't translated into a buy signal. Analyst Sebastian Bray left his rating at "Hold," acknowledging the scale of the share-price recovery while declining to recommend adding to positions. The combination is not contradictory: earnings can improve while the equity has already priced in much of the gain.

A forecast, not a company target

The distinction matters for anyone weighing the Berenberg note. An analyst estimate is neither corporate guidance nor realized profit, and the 2027 figure sits in a different layer of the accounts than the group numbers reported to date. In the third quarter of 2026, Bayer posted earnings per share of -0.69 euro, an improvement on -0.98 euro a year earlier that nonetheless left the quarter in negative territory. Revenue for the period rose to EUR 10.05 billion from EUR 9.66 billion.

Those group-level figures don't map directly onto the pharma division's projected EBITDA, and treating the more optimistic segment estimate as proof of a fully secured earnings path for the whole company would be a stretch. What the quarterly numbers do support is the broader picture of operational recovery.

Should investors sell immediately? Or is it worth buying Bayer?

Two houses, one thesis, different conclusions

UBS shares Berenberg's positive read on the drug business but not its caution on the shares. On 4 November the bank reiterated its buy recommendation and lifted its price target to EUR 66, with analyst Matthew Weston pointing to strong quarterly results and, above all, the continued pharmaceutical division. The two firms thus converge on the operational story while diverging on what investors should do about it.

Whether the bullish case holds depends on Nubeqa and Kerendia delivering in line with the more optimistic assumptions. If they do, the higher earnings forecast gains support and could invite further upward revisions to estimates. If growth merely matches existing market expectations, Berenberg's extra optimism remains unearned — and after a year like this one, even a solid performance might not be enough to generate fresh upside.

Monsanto listing is a separate, later question

Running alongside the earnings debate is a structural option that should not be conflated with it. Bray places a possible stock-market listing of Monsanto toward the end of the decade, with proceeds potentially funding pharmaceutical research and development beyond 2030. No decision has been taken, and no financing path for drug development has been agreed.

The strategic logic links Bayer's two halves: a change on the agriculture side could free up capital for medicines. Timing and execution remain open, which means the option cannot be counted as available funding today. Investors are best served by evaluating the EBITDA forecast on its own merits, independent of whether a Monsanto flotation ever happens.

Pricing politics frames the investment case

The long-term spending picture also runs through Berlin. At Bayer's "Berlin im Dialog" event, representatives from politics, business and academia debated drug supply and Germany's position as a pharmaceutical hub. IW expert Jasmina Kirchhoff noted that US drug prices average 160% above the negotiated German reimbursement rate, and warned that Trump's most-favoured-nation strategy could export price pressure to other countries and delay innovation there.

Bayer at a turning point? This analysis reveals what investors need to know now.

Germany's proposed location clause would reduce rebates for companies that invest, research, produce and create jobs domestically. The concrete funding is still missing, though a budget line was created for 2027. None of this adds to Bayer's earnings forecast, but it sets the terms on which future pharma investment will be judged.

The 24 February test

The next hard checkpoint arrives with fourth-quarter 2026 results, scheduled for 24 February 2027. What matters then is evidence that Bayer can back the elevated expectations for its pharma division with actual operating performance. Until that arrives, the standard is clear: the earnings improvement needs to become more durable, not the share-price recovery repeat itself. Only then can investors judge whether the drug business justifies a further re-rating.

Ad

Bayer Stock: New Analysis - 18 November

Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Bayer analysis...

Disclaimer...
en | DE000BAY0017 | BAYERS | boerse | 70532758 |